71 protocols found



Protocol No. Title Status
A211601 A211601: Evaluation of Mammographic Breast Density Effect of Aspirin: A companion study to Alliance Study A011502 Open (affiliates only)
NRGBR003 A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or w/o Carboplatin for Node+ or High-Risk Node- Triple-Neg Invasive Breast Cancer Open (affiliates only)
S1501 S1501: Prospective Evaluation in Prevention of Cardiac Toxicity in Patients with Metastatic HER-2+ Breast Cancer, Phase III Open (affiliates only)
S1703 Randomized Non-Inferiority Trial Comparing Overall Survival of Patients Monitored with Serum Tumor Marker Directed Disease Monitoring (STMDDM) versus Usual Care in Patient with Metastatic Hormone Receptor Positive Breast Cancer Open (affiliates only)
A011202 A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy Open
A011401 Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer Open
A011502 A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin As Adjuvant Therapy for HER2 Negative Breast Cancer: The ABC Trial Open
A221505 RT CHARM: Phase III Randomized Trial of Hypofractionated Post Mastectomy Radiation with Breast Reconstruction Open
ADVL1823 Larotrectinib (LOXO-101, NSC# 788607, IND# 141824) for Previously Untreated TRK Fusion Pediatric Solid Tumors and TRK Fusion Relapsed Pediatric Acute Leukemias Open
AGCT1531 A Phase 3 Study of Active Surveillance for Low Risk and a Randomized Trial of Carboplatin vs. Cisplatin for Standard Risk Pediatric and Adult Patients with Germ Cell Tumors Open
AGCT1532 A Randomized Phase 3 Trial of Accelerated versus Standard BEP Chemotherapy for Patients with Intermediate and Poor-risk Metastatic Germ Cell Tumors Open
ALTE15N2 LEAHRN (Late Effects After High-Risk Neuroblastoma) Study Open
APEC14B1 Project: Every Child A Registry, Eligibility Screening, Biology and Outcome Study Open
APEC1621B NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of JNJ-42756493 (Erdafitinib) in Patients with Tumors Harboring FGFR1/2/3/4 Alterations Open
APEC1621D NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of LY3023414 in Patients with Solid Tumors Open
APEC1621G NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Phase 2 Subprotocol of Vemurafenib in Patients with Tumors Harboring Braf V600 Mutations Open
APEC1621H NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 Subprotocol of Olaparib in Patients with Tumors Harboring Defects in DNA Damage Repair Genes. Open
APEC1621I NCI-COG Pediatric Match(MOLECULAR ANALYSIS FOR THERAPY CHOICE)-Phase 2 Subprotocol of Palbociclib in Patients with Tumors Harboring Activating Alterations in Cell Cycle Genes Open
APEC1621J NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)-Phase 2 Subprotocol of BVD-523FB (ulixerlinib) in Patients with Tumors Harboring Activating MAPK Pathway Mutations Open
EA1131 A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy VS Capecitabine in Patients with Residual Triple-Negative Breast Cancer following Neoaduvant Chemotherapy Open
EA1151 Tomosynthesis Mammographic Imaging Screening Trial (TMIST) Open
EAI142 [18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients with Newly Diagnosed Metastatic Breast Cancer Open
EAY131 Molecular Analysis for Therapy Choice (MATCH) Open
MA39 Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast cancer Open
MDA20160702 A Randomized, Double-blind, Placebo-controlled Study of 4-hydroxytamoxifen Topical Gel in Women with Mammographically Dense Breast Open
NCI10129 A Phase 2 Study of the PARP Inhibitor Olaparib (AZD2281) in IDH1 and IDH2 mutant Advanced Solid Tumors Open
NCI10222 A Phase II study of olaparib and AZD6738 in isocitrate dehydrogenase (IDH) mutant solid tumors Open
NRGBR004 A Randomized, Double-Blind, Phase III Trial of Paclitaxel/Trastuzumab/Pertuzumab with Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer Open
RTOG1304 A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy Open
S1418 A Randomized, Phase III Trial to Evaluate the Efficacy and Safety of MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer With 1 cm residual Invasive Cancer or Positive Lymph Node Open
UW13056 Women's Integrative Sexual Health (WISH) Program Research Database Open
UW13061 Pilot Study: Comparison of rpFNA and CNB for Breast Tissue Collection for Chemopreventive Studies Open
UW14035 Correlation of Tumorigenic Properties in Early Stage Breast Cancer: an Investigation of Tumor Types, Mitotic Phenotypes, and Tumor Microenvironment Interactions Open
UW15048 Monitoring Microwave Ablation of Breast Tumors Via Real-Time Microwave Imaging Open
UW15106 Genomic Analysis of Long-Term Survivors with Metastatic Cancer Open
UW15114 A Window of Opportunity Study of Dasatinib in Operable Triple Negative Breast Cancers with Nuclear Epidermal Growth Factor Receptor Open
UW16044 A phase I/II, single arm, non-randomized study of ribociclib (LEE011), a CDK 4/6 inhibitor in combination with bicalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer: Big Ten Cancer Research Consortium BTCRC-BRE15-024 Open
UW16063 Phase Ib 9cUAB30 in Early Stage Breast Cancer to Evaluate Biologic Effect Open
UW16088 A randoMized phAse II trIal of fulvestraNt or exemestane wiTh or without Ribociclib After progression on AntI-estrogeN therapy plus cyclin-dependent kinase 4/6 inhibition in patients with unresectable or metastatic hormone receptor positive, HER2 negative breast cancer (MAINTAIN Trial) Open
UW16106 Neoadjuvant Weekly Paclitaxel and Biomarkers of Therapy Response Open
UW16151 Pharmacodynamic biomarkers of standard anti-microtubule drugs as assessed by early tumor biopsy Open
UW17034 [18F]Fluorofuranylnorprogesterone (FFNP) PET/MR Imaging of Progesterone Receptor Expression in Invasive Breast Cancer Open
UW17064 A Phase II, Multi-center, Open Label Study of NIR-178 in Combination with PDR001 in Patients with Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma Open
UW17107 Phase 2 Study of ONC201 with and without Methionine-Restricted Diet in Patients with Metastatic Triple Negative Breast Cancer Open
UW17120 An Observational Study Profiling Biospecimens from Cancer Patients to Screen for Molecular Alterations (STRATA) Open
UW17125 Comparison of Operative to Monitoring and Endocrine Therapy (COMET) Trial for Low-Risk DCIS: A Phase III Prospective Randomized Trial (AFT-25) Open
UW17141 A Comparison of the Paravertebral Block Versus Pectoralis Block in Controlling Bilateral Post-Mastectomy Pain in Setting of Tissue Expander Open
UW17152 An Open-Label, Phase 2 Basket Study of Neratinib in Patients with Solid Tumors with Somatic Activating HER Mutations Open
UW18073 Treatment of CMV Infections with Viral-Specific T Cells Against CMV in Pediatric and Adult Immunocompromised Patients or Recipients of Allogeneic Stem Cell Transplantation Open
UW18089 A Randomized Phase II Study to Evaluate Efficacy of T-DM1 with or without Palbociclib in the Treatment of Patients with Metastatic HER2 Positive Breast Cancer Open
UW18099 A Phase II Study of Real-Time MRI-Guided 3-Fraction Accelerated Partial Breast Irradiation in Early Breast Cancer (MAPBI) Open
UW18101 Evaluating the Use of Enhanced Recovery Preoperative Immunonutrition and Carbohydrate Loading Strategies in Immediate Autologous and Alloplastic Breast Reconstruction Open
UW18107 Phase 2 Trial with Safety Run-In of Gedatolisib Plus Talazoparib in Advanced Triple Negative or BRCA1/2 Positive, HER2 Negative Breast Cancers Open
UW18110 A Phase I/II Study of OAR-Based, Dose Escalated SBRT with Real Time Adaptive MRI Guidance for Liver Metastases Open
UW18113 An Open-Label, Multicenter, Phase 1/2 Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors Open
UW18133 A Multicenter, Open-label Phase 2 Study of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) in Previously Treated Subjects with Selected Solid Tumors (LEAP-005) Open
UW19004 Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors Open
UW19035 An Open-Label Randomized Phase 2 trial of SAR439859, versus Endocrine Monotherapy as per Physician's Choice in Patients with Estrogen Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer with Prior Exposure to Hormonal Therapies Open
UW19038 Symptom Cluster Experience of Cancer Patient-Caregiver Dyads Open
UW19040 Engaging Stakeholders to Improve the Quality of Breast Cancer Follow-up: Focus Groups of Survivors and Oncologists Open
UW19046 A Pilot Study of FES Imaging to Optimize Tamoxifen Dose for Metastatic Breast Cancer Patients with ESR1 Mutations Open
UW19056 Determining FDG PET/CT Repeatability in Patients with Solid Tumor Open
UW19075 A Phase 1b Study to Evaluate the Safety and Clinical Activity of AB122 in Biomarker-Selected Participants with Advanced Solid Tumors Open
UW19080 A Phase 1b/2, Open-Label, Multicenter Dose-Escalation and Dose-Expansion Study of the Combination of RMC-4630 with Cobimetinib in Adult Participants with Relapsed/Refractory Solid Tumors and a Phase 1b Study of RMC-4630 with Osimertinib in Participants with Epidermal Growth Factor Receptor Mutation Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Open
UW19082 Symptom Burden, Co-Occurrence, and Trajectories in Children with Advanced Cancer Open
UW19092 Hormone Replacement Therapy Use by Women at High risk of Breast and Ovarian Cancer after Bilateral Risk-Reducing Salpingo-Oophorectomy Open
UW19115 Engaging Stakeholders to Improve the Quality of Breast Cancer Follow-up: a Pilot Study to Assess Survivors Symptoms and Concerns Open
UW19136 A Phase 2, Open-Label, Single-Arm, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib in Participants With Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) Open
UW19140 A Phase 1b/2, Open label, Dose Escalation and Expansion Study of the Glutaminase Inhibitor Telaglenastat (CB-839) in Combination with the CDK4/6 Inhibitor Palbociclib in Patients with Advanced or Metastatic Solid Tumors Open
UW20000 An Open-label, Multicenter, Multicohort, Phase 2 Study to Evaluate Enfortumab Vedotin in Subjects with Previously Treated Locally Advanced or Metastatic Malignant Solid Tumors (EV-202) Open
UW20046 A Phase 2 Study of Futibatinib in Patients with Specific FGFR Aberrations Open